US prosecutors have moved to dismiss charges of alleged fentanyl trafficking against an Indian pharmaceutical executive, marking a rare reversal in Washington’s intensifying campaign against the global supply chain of synthetic opioids.
The decision shifts attention back to India’s role in the trade, after recent intelligence reports identified the country as a growing supplier of precursor chemicals used in illicit fentanyl production.
The development also highlights the challenges faced by authorities in proving cases against individuals and companies operating in a complex international pharmaceutical market, where regulatory approvals and legitimate trade coexist with allegations of illegal diversion.
Case against Vasudha executive dismissed
On Thursday, prosecutors in Washington asked a federal judge to dismiss charges against Venkata Naga Madhusudhan Raju Manthena, marketing director at Hyderabad-based Vasudha Pharma Chem Ltd.
Manthena was indicted in March alongside the company and two other executives, accused of conspiring to distribute chemicals that could be used to manufacture fentanyl.
The court filing stated prosecutors had “learned additional information that has changed the Government’s view” of the evidence against him.
The charges against the other two Vasudha executives remain in place, as does the indictment against the company. Neither the firm nor its leadership in India face charges within the country.
India’s growing scrutiny in the fentanyl trade
The move comes as India faces increasing scrutiny from US authorities in the global fight against fentanyl, which has fuelled a public health crisis in America.
While enforcement has historically focused on Canada, Mexico, and China, a US intelligence report in March identified India as the world’s second-largest supplier of illicit fentanyl precursor chemicals and pill-pressing equipment, after China.
The indictment of Vasudha Pharma in March made it the most prominent Indian pharmaceutical firm to be pulled into the US crackdown. Vasudha manufactures active pharmaceutical ingredients and drug intermediates, supplying both domestic and global clients.
The company holds regulatory approvals from the US Food and Drug Administration and reported revenues of more than 11.5 billion rupees ($130 million) in the fiscal year ending March 2024, according to India Ratings and Research.
US prosecutors have also taken action against other Indian companies this year. In January, Athos Chemicals Pvt. and Raxuter Chemicals, both based in Gujarat, were indicted on fentanyl-related charges.
Raxuter’s founder, Bhavesh Lathiya, was arrested and has pleaded not guilty. Athos has not entered a plea and has not responded publicly.
Wider context of US trade and enforcement
India’s involvement in the fentanyl crackdown intersects with broader trade tensions. Former US President Donald Trump imposed tariffs on India, alongside Canada, Mexico, and China, accusing these nations of failing to do enough to stem the fentanyl supply chain.
India was already a focus of US tariffs over its purchases of discounted Russian oil, further complicating the trade relationship.
The Vasudha case illustrates the complexity of prosecuting companies with dual identities — operating legally within regulated pharmaceutical markets while facing allegations of facilitating illegal drug production.
The dismissal of charges against Manthena underscores these challenges and leaves the wider case against Vasudha and its executives ongoing.
Ongoing cases highlight enforcement challenges
The Department of Justice’s pursuit of Indian companies is part of a broader effort to target upstream suppliers in the fentanyl trade.
The arrest of Raxuter’s founder in January shows that prosecutions can advance, but the dismissal of charges against Vasudha’s executive demonstrates the difficulties of gathering sufficient evidence in cross-border cases.
No timeline has been given for the next steps in the Vasudha case, and US prosecutors have not indicated whether further indictments against Indian firms may follow.
For now, the spotlight remains on India as it emerges as a critical player in the supply chain of precursor chemicals at the centre of the global fentanyl crisis.
The post US prosecutors drop fentanyl trafficking charges against Indian pharma executive appeared first on Invezz
